[go: up one dir, main page]

MX2021000542A - Apirasas solubilizadas, metodos y usos. - Google Patents

Apirasas solubilizadas, metodos y usos.

Info

Publication number
MX2021000542A
MX2021000542A MX2021000542A MX2021000542A MX2021000542A MX 2021000542 A MX2021000542 A MX 2021000542A MX 2021000542 A MX2021000542 A MX 2021000542A MX 2021000542 A MX2021000542 A MX 2021000542A MX 2021000542 A MX2021000542 A MX 2021000542A
Authority
MX
Mexico
Prior art keywords
solubilized
methods
apirases
preventing
design
Prior art date
Application number
MX2021000542A
Other languages
English (en)
Inventor
Thomas Huber
Chao Zou
Hilmar Ebersbach
Boerje Haraldsson
Agostino Cirillo
Guido Junge
Regina Link
Max Warncke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021000542A publication Critical patent/MX2021000542A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

La invención se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.
MX2021000542A 2018-07-18 2019-07-17 Apirasas solubilizadas, metodos y usos. MX2021000542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18
PCT/IB2019/056117 WO2020016804A1 (en) 2018-07-18 2019-07-17 Solubilized apyrases, methods and use

Publications (1)

Publication Number Publication Date
MX2021000542A true MX2021000542A (es) 2021-03-29

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000542A MX2021000542A (es) 2018-07-18 2019-07-17 Apirasas solubilizadas, metodos y usos.

Country Status (27)

Country Link
US (2) US12325870B2 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR102919646B1 (es)
CN (6) CN119020319A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU24746B1 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
MY (1) MY203583A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TWI857965B (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
US20230242965A1 (en) * 2020-05-28 2023-08-03 Charm Sciences, Inc. Methods and assemblies for sample analysis
CA3262308A1 (en) 2022-07-29 2024-02-01 Novartis Ag IMPROVED PRODUCTION OF CD39 VARIANTS
EP4561608A1 (en) 2022-07-29 2025-06-04 Novartis AG Treatment for acute organ injury using cd39, recombinant cd39
WO2025080755A1 (en) * 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
WO2000023094A2 (en) 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
US6867177B2 (en) * 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
WO2008002157A1 (en) 2006-06-27 2008-01-03 Agresearch Limited Apyrases and uses thereof
US8535662B2 (en) 2010-01-13 2013-09-17 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
JP5913130B2 (ja) * 2010-01-13 2016-04-27 エイピーティー セラピューティックス，インク． 治療用アピラ−ゼ構築物、アピラ−ゼ作用物質、及び製造方法
RU2712507C2 (ru) 2013-12-20 2020-01-29 Новартис Аг Новые эукариотические клетки и способы их получения для рекомбинантной экспрессии представляющего интерес продукта
AU2014369175B2 (en) 2013-12-20 2017-03-02 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
AR115790A1 (es) 2021-02-24
AU2019306821B2 (en) 2022-09-29
CR20210021A (es) 2021-03-23
CU24746B1 (es) 2025-04-04
KR102919646B1 (ko) 2026-01-29
AU2019306821A1 (en) 2020-12-24
CN112424346A (zh) 2021-02-26
TWI857965B (zh) 2024-10-11
US20250179447A1 (en) 2025-06-05
ECSP21002804A (es) 2021-04-29
JP7425784B2 (ja) 2024-01-31
CN119162148A (zh) 2024-12-20
PE20210185A1 (es) 2021-02-02
PH12021550122A1 (en) 2021-09-27
US20220356455A1 (en) 2022-11-10
CL2021000129A1 (es) 2021-08-20
CN119020320A (zh) 2024-11-26
KR20210035806A (ko) 2021-04-01
CU20210008A7 (es) 2021-08-06
BR112021000586A2 (pt) 2021-04-06
IL280191A (en) 2021-03-01
CN112424346B (zh) 2024-08-06
CN119020318A (zh) 2024-11-26
JOP20210008A1 (ar) 2021-01-12
US12325870B2 (en) 2025-06-10
UY38299A (es) 2020-02-28
JP2024023297A (ja) 2024-02-21
MA53177A (fr) 2021-05-26
MY203583A (en) 2024-07-05
EP3824079A1 (en) 2021-05-26
CN119020319A (zh) 2024-11-26
CA3103684A1 (en) 2020-01-23
TW202016299A (zh) 2020-05-01
WO2020016804A1 (en) 2020-01-23
SG11202011776RA (en) 2021-02-25
CO2021000210A2 (es) 2021-01-18
ZA202007187B (en) 2022-06-29
CN119020321A (zh) 2024-11-26
JP2021529550A (ja) 2021-11-04
EA202190057A1 (ru) 2021-08-24

Similar Documents

Publication Publication Date Title
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX378273B (es) Compuestos activos hacia bromodominios.
MX2019014041A (es) Inhibidores pirazolicos de magl.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
CL2015002897A1 (es) Inhibidores de bace1
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202090270A1 (ru) Новые замещенные производные ксантина
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX383460B (es) Derivados peptidicos novedosos y sus usos.
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
LT3758799T (lt) Kompozicija, skirta odos pažaidų, sukeltų apšvietimo, profilaktikai ir gydymui